HIV

Study finds substantial minority living with undiagnosed HIV infection.

Advocates seek to eradicate the disease by 2030.

Study suggests testing sites in high schools may increase the likelihood of getting an HIV test.

Pharmacists vital in helping HIV-infected women stay adherent to their treatment regimen.

Pregnancy is an important time for women with human immunodeficiency virus (HIV) to receive adequate prenatal care, antiretroviral therapy (ART), and postpartum HIV care to improve clinical outcomes for themselves and their babies.

Device may eventually detect cancer and diabetes.

Researchers target the spread of diseases such as HIV, SARS, and Ebola.

Proper nutrition leads to improved outcomes and increased CD4 T-cell counts.

Top infectious diseases articles for pharmacotherapy from last year.

Each year, the American Society of Health-System Pharmacists provides a tremendous service to pharmacists by publishing a list of significant articles on infectious diseases pharmacotherapy from the previous year.

Children vaccinated before starting HIV therapy found to be at risk.

Research may lead to a gel that instantly destroys viral particles.

Program addresses the needs of minority and minority-serving clinicians and their communities.

For more than 25 years, the Midwest AIDS Training + Education Center has educated clinicians who provide care to patients infected with human immunodeficiency virus (HIV) and those at risk for HIV.

Compound targets latent HIV proteins without harming other parts of the body.

States need to target specific populations affected by HIV outbreaks.

A clinic sees improved viral suppression rates as a result of comprehensive medication review, medication synchronization, and patient outreach services.

Pharmacists can help patients understand insurance issues and guide patients to assistance programs.

The public fear of human immunodeficiency virus has diminished since the 1980s crisis, and now many health care professionals are seeing less urgency surrounding HIV prevention and treatment.

Updated information includes drug-drug interaction.

Despite inducing anti-HIV antibodies, vaccine in HVTN 505 trial still not protective.

Liver damage progresses at a more rapid pace in patients with HIV.

Compound reduces residual levels from infected dormant cells.

Test distinguishes between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

The first diagnostic test that can differentiate between types of HIV infection has been approved by the FDA.

Antibodies critical to stopping spread of viral cells.

The dispensing model for pyrimethamine has changed, which may cause delays in therapy.